Search

Your search keyword '"Rossetti, Sabrina"' showing total 249 results
Start Over Author "Rossetti, Sabrina"
249 results on '"Rossetti, Sabrina"'

1. Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study

Author

Patrikidou, Anna, Saieva, Calogero, Lee-Ying, Richard, Nuzzo, Pier Vitale, Zarif, Talal El, McClure, Heather, Davidsohn, Matthew, Eid, Marc, Spinelli, Gian Paolo, Catalano, Fabio, Cremante, Malvina, Fotia, Giuseppe, Rossetti, Sabrina, Valenca, Loana, Vauchier, Charles, Ottanelli, Carlotta, Andrade, Livia, Gennusa, Vincenzo, Mestre, Ricardo Pereira, Fornarini, Giuseppe, Pignata, Sandro, Procopio, Giuseppe, Santini, Daniele, Ravi, Praful, Sweeney, Christopher, Heng, Daniel, De Giorgi, Ugo, Fizazi, Karim, Russo, Antonio, and Francini, Edoardo

Published
2024
Full Text
View/download PDF

3. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study

Author

Fotia, Giuseppe, Saieva, Calogero, Lee-Ying, Richard, Patrikidou, Anna, Nuzzo, Pier Vitale, Zanardi, Elisa, Rossetti, Sabrina, Davidsohn, Matthew, Eid, Marc, El Zarif, Talal, McClure, Heather, Spinelli, Gian Paolo, Damassi, Alessandra, Murianni, Veronica, Vauchier, Charles, Oliveira, Thiago Martins, Malgeri, Andrea, Modesti, Mikol, Mestre, Ricardo Pereira, Valenca, Loana, Ravi, Praful, Santini, Daniele, Pignata, Sandro, De Giorgi, Ugo, Sweeney, Christopher, Heng, Daniel, Procopio, Giuseppe, Russo, Antonio, and Francini, Edoardo

Published
2024
Full Text
View/download PDF

4. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

Author

Altavilla, Amelia, Atzori, Francesco, Banna, Giuseppe Luigi, Barni, Sandro, Basso, Umberto, Bauckneht, Matteo, Berardi, Rossana, Berruti, Alfredo, Bertoldo, Francesco, Bimbatti, Davide, Boccardo, Francesco, Buti, Sebastiano, Buttigliero, Consuelo, Caffo, Orazio, Calabrò, Fabio, Cattrini, Carlo, Cellini, Francesco, Conteduca, Vincenza, Cursano, Maria Concetta, De Feo, Giulia, De Giorgi, Ugo, Di Lorenzo, Giuseppe, Di Maio, Massimo, Di Napoli, Marilena, Ermacora, Paola, Fornarini, Giuseppe, Fratino, Lucia, Fusco, Vittorio, Gernone, Angela, Ibrahim, Toni, Lanzetta, Gaetano, Malgeri, Andrea, Maruzzo, Marco, Masini, Cristina, Messina, Carlo, Mosca, Alessandra, Naglieri, Emanuele, Nolè, Franco, Ortega, Cinzia, Palermo, Andrea, Pantano, Francesco, Prati, Veronica, Procopio, Giuseppe, Rescigno, Pasquale, Roberto, Michela, Rossetti, Sabrina, Roviello, Giandomenico, Santini, Daniele, Stellato, Marco, Tambaro, Rosa, Toma, Ilaria, Tucci, Marcello, Valsecchi, Anna Amela, Verzoni, Elena, Zanardi, Elisa, Zucali, Paolo Andrea, Cursano, M.C., Valsecchi, A.A., Pantano, F., Di Maio, M., Procopio, G., Berruti, A., Bertoldo, F., Tucci, M., De Giorgi, U., and Santini, D.

Published
2024
Full Text
View/download PDF

6. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Author

Nuzzo, Pier Vitale, Pederzoli, Filippo, Saieva, Calogero, Zanardi, Elisa, Fotia, Giuseppe, Malgeri, Andrea, Rossetti, Sabrina, Valenca Bueno, Loana, Andrade, Livia Maria Q. S., Patrikidou, Anna, Mestre, Ricardo Pereira, Modesti, Mikol, Pignata, Sandro, Procopio, Giuseppe, Fornarini, Giuseppe, De Giorgi, Ugo, Russo, Antonio, and Francini, Edoardo

Published
2023
Full Text
View/download PDF

8. Transcriptional profiling of patients with metastatic hormone-sensitive prostate cancer to uncover specific signatures linked to the transition from androgen-dependent to androgen-independent phenotype.

Author

Pecoraro, Giovanna, Esposito, Daniela, Belli, Stefania, Di Costanzo, Fabrizio, Migliaccio, Fortuna, Messina, Francesca, Pepe, Felice, Varricchio, Silvia, Caruso, Marco, Scagliarini, Sarah, Rossetti, Sabrina, Crocetto, Felice, Conteduca, Vincenza, Sanguedolce, Francesca, Malapelle, Umberto, Imbimbo, Ciro, Servetto, Alberto, Bianco, Roberto, and Formisano, Luigi

Published
2025
Full Text
View/download PDF

9. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study

Author

Procopio, Giuseppe, Chiuri, Vincenzo, Mantini, Giovanna, Roberto Bordonaro, Roberto Maisano., Cinieri, Saverio, Rossetti, Sabrina, De Placido, Sabino, Airoldi, Mario, Galli, Luca, Gasparro, Donatello, Ludovico, Giuseppe Mario, Guglielmini, Pamela Francesca, Santini, Daniele, Naglieri, Emanuele, Fagnani, Daniele, Aglietta, Massimo, Livi, Lorenzo, Schips, Luigi, Passalacqua, Rodolfo, Fiore, Michele, D'Angelillo, Rolando Maria, Ceresoli, Giovanni Luca, Magrini, Stefano, Rondonotti, David, Mirone, Vincenzo, Ferriero, Maria Consiglia, Sciarra, Alessandro, Acquati, Mirko, Boccardo, Francesco, Scagliotti, Giorgio Vittorio, Mencoboni, Manlio, De Giorgi, Ugo, Micheletti, Gennaro, Lanzetta, Gaetano, Sartori, Donata, Carlini, Paolo, Soto Parra, Hector Josè, Battaglia, Michele, Uricchio, Francesco, Bernardo, Antonio, De Lisa, Antonello, Carrieri, Giuseppe, Ardizzoia, Antonio, Aieta, Michele, Pisconti, Salvatore, Marchetti, Paolo, Paiar, Fabiola, Procopio, G., Chiuri, V.E., Giordano, M., Alitto, A.R., Maisano, R., Bordonaro, R., Cinieri, S., Rossetti, S., De Placido, S., Airoldi, M., Galli, L., Gasparro, D., Ludovico, G.M., Guglielmini, P.F., Carella, C., Nova, P., Aglietta, M., Schips, L., Beccaglia, P., Sciarra, A., Livi, L., and Santini, D.

Published
2022
Full Text
View/download PDF

10. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

Author

Caffo, Orazio, Ortega, Cinzia, Nolè, Franco, Gasparro, Donatello, Mucciarini, Claudia, Aieta, Michele, Zagonel, Vittorina, Iacovelli, Roberto, De Giorgi, Ugo, Facchini, Gaetano, Veccia, Antonello, Palesandro, Erica, Verri, Elena, Buti, Sebastiano, Razzini, Giorgia, Bozza, Giovanni, Maruzzo, Marco, Ciccarese, Chiara, Schepisi, Giuseppe, Rossetti, Sabrina, Maines, Francesca, Kinspergher, Stefania, Fratino, Lucia, Ermacora, Paola, Nicodemo, Maurizio, Giordano, Monica, Sartori, Donata, Scapoli, Daniela, Sabbatini, Roberto, Lo Re, Giovanni, Morelli, Franco, D’Angelo, Alessandro, Vittimberga, Isabella, Lippe, Paolo, Carrozza, Francesco, Messina, Caterina, Galli, Luca, Valcamonico, Francesca, Porta, Camillo, Pappagallo, Giovanni, and Aglietta, Massimo

Published
2021
Full Text
View/download PDF

11. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

Author

Vitale, Maria Giuseppa, Pipitone, Stefania, Venturelli, Marta, Baldessari, Cinzia, Porta, Camillo, Iannuzzi, Federica, Basso, Umberto, Scagliarini, Sarah, Zucali, Paolo Andrea, Galli, Luca, Rossetti, Sabrina, Caserta, Claudia, Bracarda, Sergio, Iacovelli, Roberto, Masini, Cristina, Cortellini, Alessio, Di Girolamo, Stefania, Buti, Sebastiano, Fornarini, Giuseppe, Carrozza, Francesco, Santoni, Matteo, Caputo, Francesco, Giaquinta, Stefania, Balduzzi, Sara, D’Amico, Roberto, Vitale, Giovanna, Mighali, Pasquale, and Sabbatini, Roberto

Published
2020
Full Text
View/download PDF

12. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

Author

Iacovelli, Roberto, Ciccarese, Chiara, Facchini, Gaetano, Milella, Michele, Urbano, Federica, Basso, Umberto, De Giorgi, Ugo, Sabbatini, Roberto, Santini, Daniele, Berardi, Rossana, Santoni, Matteo, Bracarda, Sergio, Massari, Francesco, Masini, Cristina, De Tursi, Michele, Ricotta, Riccardo, Buti, Sebastiano, Zustovich, Fable, Sepe, Pierangela, Rossetti, Sabrina, Maruzzo, Marco, Cortesi, Enrico, Tortora, Giampaolo, and Procopio, Giuseppe

Published
2020
Full Text
View/download PDF

16. Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

Author

Borzillo, Valentina, primary, Scipilliti, Esmeralda, additional, Pezzulla, Donato, additional, Serra, Marcello, additional, Ametrano, Gianluca, additional, Quarto, Giuseppe, additional, Perdonà, Sisto, additional, Rossetti, Sabrina, additional, Pignata, Sandro, additional, Crispo, Anna, additional, Di Gennaro, Piergiacomo, additional, D’Alesio, Valentina, additional, Arrichiello, Cecilia, additional, Buonanno, Francesca, additional, Mercogliano, Simona, additional, Russo, Antonio, additional, Tufano, Antonio, additional, Di Franco, Rossella, additional, and Muto, Paolo, additional

Published
2023
Full Text
View/download PDF

18. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

Author

Facchini, Gaetano, Rossetti, Sabrina, Berretta, Massimiliano, Cavaliere, Carla, Scagliarini, Sarah, Vitale, Maria Giuseppa, Ciccarese, Chiara, Di Lorenzo, Giuseppe, Palesandro, Erica, Conteduca, Vincenza, Basso, Umberto, Naglieri, Emanuele, Farnesi, Azzurra, Aieta, Michele, Borsellino, Nicolò, La Torre, Leonardo, Iovane, Gelsomina, Bonomi, Lucia, Gasparro, Donatello, Ricevuto, Enrico, De Tursi, Michele, De Vivo, Rocco, Lo Re, Giovanni, Grillone, Francesco, Marchetti, Paolo, De Vita, Ferdinando, Scavelli, Claudio, Sini, Claudio, Pisconti, Salvatore, Crispo, Anna, Gebbia, Vittorio, Maestri, Antonio, Galli, Luca, De Giorgi, Ugo, Iacovelli, Roberto, Buonerba, Carlo, Cartenì, Giacomo, and D’Aniello, Carmine

Published
2019
Full Text
View/download PDF

19. Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

Author

Iacovelli, Roberto, Ciccarese, Chiara, Facchini, Gaetano, Milella, Michele, Urbano, Federica, Basso, Umberto, De Giorgi, Ugo, Sabbatini, Roberto, Santini, Daniele, Berardi, Rossana, Santoni, Matteo, Bracarda, Sergio, Massari, Francesco, Masini, Cristina, De Tursi, Michele, Ricotta, Riccardo, Buti, Sebastiano, Zustovich, Fable, Sepe, Pierangela, Rossetti, Sabrina, Maruzzo, Marco, Cortesi, Enrico, Tortora, Giampaolo, and Procopio, Giuseppe

Published
2020
Full Text
View/download PDF

20. Comparison of [68Ga]Ga-PSMA-11, [18F]PSMA1007 and [177Lu]Lu-PSMA-617 in detecting the same prostate cancer lesions. The evidences from the clinical practice in a dedicated Cancer Institution

Author

de Marino, Roberta, Morisco, Anna, Maisto, Costantina, Di Gennaro, Francesca, Rossi, Alfredo, Carideo, Luciano, Raddi, Marco, Rossetti, Sabrina, Maiolino, Piera, Pignata, Sandro, and Lastoria, Secondo

Subjects
PCa, mCRPC, [68Ga]Ga-PSMA-11, [18F]PSMA-1007, SUVmax, [177Lu]Lu-PSMA-617, RLT, PSA
Abstract

Background. PET/CT with radiolabeled PSMA inhibitors gained clinical relevance in the imaging and therapy of mCRPC patients. Different PSMA radioligands are currently available for PET imaging but few data exist on comparative rate of detection, degree of uptake, correlation with RLT effectiveness, levels of PSA and disease symptoms. Methods. Fifteen mCRPC patients underwent to [68Ga]Ga-PSMA-11/[18F]PSMA-1007 PET/CT imaging, and to 4 up to 6 [177Lu]Lu-PSMA-617 RLT cycles (n. 6). The detection rate and the uptake in target lesions or in normal organs were compared to highlight similarities and differences. Results. [68Ga]/[18F]-PSMA-radioligands show similar rates of detection with overlapping levels of uptake in PCa sites, that is different in normal organs. In the six patients who completed RLT, [177Lu]Lu-PSMA-617 targeted the same lesions causing a drastic reduction in SUVmax after the second dose. Conclusions. These three PSMA radioligands concentrated in the same foci of PCa disease. Thus, the choice for PET imaging may be defined adopting the following parameters: local availability, costs of production/purchasing, number of studies and clinical demands for PET/CT per session. The use of PET radioligands did not influence a proper selection of patients to treat by RLT.

Published
2023
Full Text
View/download PDF

21. sj-doc-1-tam-10.1177_17588359231156147 – Supplemental material for Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Author

Nuzzo, Pier Vitale, Ravera, Francesco, Saieva, Calogero, Zanardi, Elisa, Fotia, Giuseppe, Malgeri, Andrea, Rossetti, Sabrina, Valença, Loana Bueno, Oliveira, Thiago Martins, Vauchier, Charles, Pereira Mestre, Ricardo, Modesti, Mikol, Patrikidou, Anna, Pignata, Sandro, Procopio, Giuseppe, Fornarini, Giuseppe, De Giorgi, Ugo, Russo, Antonio, and Francini, Edoardo

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-doc-1-tam-10.1177_17588359231156147 for Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer by Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Bueno Valença, Thiago Martins Oliveira, Charles Vauchier, Ricardo Pereira Mestre, Mikol Modesti, Anna Patrikidou, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo and Edoardo Francini in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

22. Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study.

Author

Lee-Ying, Richard M., primary, Saieva, Calogero, additional, Nuzzo, Pier Vitale, additional, Malgeri, Andrea, additional, Fotia, Giuseppe, additional, Zanardi, Elisa, additional, Rossetti, Sabrina, additional, Valenca, Loana Bueno, additional, Patrikidou, Anna, additional, Modesti, Mikol, additional, Martins Oliveira, Thiago, additional, Pignata, Sandro, additional, Fornarini, Giuseppe, additional, Procopio, Giuseppe, additional, Santini, Daniele, additional, Sweeney, Christopher, additional, Heng, Daniel Yick Chin, additional, De Giorgi, Ugo, additional, Russo, Antonio, additional, and Francini, Edoardo, additional

Published
2023
Full Text
View/download PDF

23. Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.

Author

Gennusa, Vincenzo, primary, Saieva, Calogero, additional, Lee-Ying, Richard M., additional, Nuzzo, Pier Vitale, additional, Spinelli, Gian Paolo, additional, Zanardi, Elisa, additional, Fotia, Giuseppe, additional, Rossetti, Sabrina, additional, Valenca, Loana Bueno, additional, Patrikidou, Anna, additional, Andrade, Livia, additional, Pereira Mestre, Ricardo, additional, Fornarini, Giuseppe, additional, Procopio, Giuseppe, additional, Santini, Daniele, additional, Sweeney, Christopher, additional, Heng, Daniel Yick Chin, additional, De Giorgi, Ugo, additional, Russo, Antonio, additional, and Francini, Edoardo, additional

Published
2023
Full Text
View/download PDF

24. Real-world outcomes of docetaxel (DOC) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC): First analysis from an Italian multicenter observational study (ECHOS trial).

Author

Caffo, Orazio, primary, Basso, Umberto, additional, Cavasin, Nicolò, additional, Facchini, Gaetano, additional, Catalano, Fabio, additional, Nicodemo, Maurizio, additional, Sorarù, Mariella, additional, Ermacora, Paola, additional, Galli, Luca, additional, Cattrini, Carlo, additional, Borsellino, Nicolo, additional, Sirotova, Zuzana, additional, Rossetti, Sabrina, additional, Grillone, Francesco, additional, Zucali, Paolo Andrea, additional, Ortega, Cinzia, additional, Ricotta, Riccardo, additional, Valcamonico, Francesca, additional, Vittimberga, Isabella, additional, and Buttigliero, Consuelo, additional

Published
2023
Full Text
View/download PDF

25. The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer

Author

Passarelli, Anna, primary, Ventriglia, Jole, additional, Pisano, Carmela, additional, Cecere, Sabrina Chiara, additional, Napoli, Marilena Di, additional, Rossetti, Sabrina, additional, Tambaro, Rosa, additional, Tarotto, Luca, additional, Fiore, Francesco, additional, Farolfi, Alberto, additional, Bartoletti, Michele, additional, and Pignata, Sandro, additional

Published
2023
Full Text
View/download PDF

26. Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Author

Nuzzo, Pier Vitale, primary, Ravera, Francesco, additional, Saieva, Calogero, additional, Zanardi, Elisa, additional, Fotia, Giuseppe, additional, Malgeri, Andrea, additional, Rossetti, Sabrina, additional, Valença, Loana Bueno, additional, Oliveira, Thiago Martins, additional, Vauchier, Charles, additional, Pereira Mestre, Ricardo, additional, Modesti, Mikol, additional, Patrikidou, Anna, additional, Pignata, Sandro, additional, Procopio, Giuseppe, additional, Fornarini, Giuseppe, additional, De Giorgi, Ugo, additional, Russo, Antonio, additional, and Francini, Edoardo, additional

Published
2023
Full Text
View/download PDF

27. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma

Author

Iacovelli, Roberto, Cossu Rocca, Maria, Galli, Luca, Sabbatini, Roberto, De Giorgi, Ugo, Santini, Daniele, Facchini, Gaetano, Mosca, Alessandra, Atzori, Francesco, Zucali, Paolo, Fornarini, Giuseppe, Massari, Francesco, Buti, Sebastiano, Ricotta, Riccardo, Masini, Cristina, Toscani, Ilaria, Biasco, Elisa, Guida, Annalisa, Lolli, Cristian, De Lisi, Delia, Rossetti, Sabrina, Terrone, Carlo, Scartozzi, Mario, Miggiano, Chiara, Pastorino, Alessandro, Bersanelli, Melissa, Carlo-Stella, Giulia, Pinto, Carmine, Nobili, Elisabetta, Nolè, Franco, Tortora, Giampaolo, and Porta, Camillo

Published
2018
Full Text
View/download PDF

28. Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.

Author

Di Costanzo, Fabrizio, Napolitano, Fabiana, Salomone, Fabio, Amato, Anna Rita, Alberico, Gennaro, Migliaccio, Fortuna, Pecoraro, Giovanna, Marra, Annachiara, Crocetto, Felice, Ruffo, Antonio, Scagliarini, Sarah, Rossetti, Sabrina, Puglia, Livio, Di Napoli, Marilena, Bianco, Roberto, Servetto, Alberto, and Formisano, Luigi

Subjects
ONLINE information services, GENITOURINARY organ tumors, SYSTEMATIC reviews, HEALTH status indicators, TUMOR classification, QUALITY of life, DESCRIPTIVE statistics, RESEARCH funding, MEDLINE
Abstract

Simple Summary: In this manuscript, we investigate the reporting rate of health-related quality of life (HRQoL) in phase III RCTs evaluating therapies in advanced genitourinary cancers published between 2010 and 2022. Results showed underreporting of HRQoL and the need to dedicate more attention to its assessment. Background: As recommended in the European Society for Medical Oncology (ESMO) guidelines, assessment of health-related quality of life (HRQoL) should be a relevant endpoint in randomized controlled trials (RCTs) testing new anticancer therapies. However, previous publications by our group and others revealed a frequent underestimation and underreporting of HRQoL results in publication of RCTs in oncology. Herein, we systematically reviewed HRQoL reporting in RCTs testing new treatments in advanced prostate, kidney and urothelial cancers and published between 2010 and 2022. Methods: We searched PubMed RCTs testing novel therapies in genitourinary (GU) cancers and published in fifteen selected journals (Annals of Oncology, BMC Cancer, British Journal of Cancer, Cancer Discovery, Clinical Cancer Research, Clinical Genitourinary cancer, European Journal of Cancer, European Urology, European Urology Oncology, JAMA, JAMA Oncology, Journal of clinical Oncology, Lancet, Lancet Oncology and The New England Journal of Medicine). We excluded trials investigating exclusively best supportive care or behavioral intervention, as well as subgroup or post hoc analyses of previously published trials. For each RCT, we investigated whether HRQoL assessment was performed by protocol and if results were reported in the primary manuscript or in a secondary publication. Results: We found 85 eligible trials published between 2010 and 2022. Only 1/85 RCTs (1.2%) included HRQoL among primary endpoints. Of note, 25/85 (29.4%) RCTs did not include HRQoL among study endpoints. HRQoL results were non-disclosed in 56/85 (65.9%) primary publications. Only 18/85 (21.2%) publications fulfilled at least one item of the CONSORT-PRO checklist. Furthermore, 14/46 (30.4%) RCTs in prostate cancer, 12/25 (48%) in kidney cancer and 3/14 (21.4%) in urothelial cancer reported HRQoL data in primary publications. Next, HRQoL data were disclosed in primary manuscripts of 12/32 (37.5%), 5/13 (38.5%), 5/16 (31.3%) and 5/15 (33.3%) trials evaluating target therapies, chemotherapy, immunotherapy and new hormonal agents, respectively. Next, we found that HRQoL data were reported in 16/42 (38%) and in 13/43 (30.2%) positive and negative trials, respectively. Finally, the rate of RCTs reporting HRQoL results in primary or secondary publications was 55.3% (n = 47/85). Conclusions: Our analysis revealed a relevant underreporting of HRQoL in RCTs in advanced GU cancers. These results highlight the need to dedicate more attention to HRQoL in RCTs to fully assess the value of new anticancer treatments. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer

Author

Passarelli, Anna, primary, Pisano, Carmela, additional, Cecere, Sabrina Chiara, additional, Di Napoli, Marilena, additional, Rossetti, Sabrina, additional, Tambaro, Rosa, additional, Ventriglia, Jole, additional, Gherardi, Federica, additional, Iannacone, Eva, additional, Venanzio, Sergio Setola, additional, Fiore, Francesco, additional, Bartoletti, Michele, additional, Scognamiglio, Giosuè, additional, Califano, Daniela, additional, and Pignata, Sandro, additional

Published
2022
Full Text
View/download PDF

31. Feasibility of cabazitaxel in octogenarian prostate cancer patients

Author

Tralongo, Paolo, primary, Bordonaro, Sebastiano, additional, Di Lorenzo, Giuseppe, additional, De Giorgi, Ugo, additional, Borsellino, Nicolò, additional, Facchini, Gaetano, additional, Rossetti, Sabrina, additional, Fornarini, Giuseppe, additional, Longo, Vito, additional, Tralongo, Antonino Carmelo, additional, Caspani, Francesca, additional, Spada, Massimiliano, additional, Calvani, Nicola, additional, and Carlini, Paolo, additional

Published
2022
Full Text
View/download PDF

32. Reirradiation of locally recurrent prostate cancer with Cyber-knife® System or Volumetric Modulated Arc Therapy (VMAT) and IGRT-Clarity®: outcomes, toxicities and dosimetric evalu-ation

Author

Di Franco Rossella, Borzillo Valentina, Scipilliti Esmeralda, Ametrano Gianluca, Marcello, Serra, Arrichiello Cecilia, Federica, Savino, De Martino Fortuna, D'Alesio Valentina, Cammarota Fabrizio, Crispo Anna, Pignata Sandro, Rossetti Sabrina, Giuseppe, Quarto, and Muto Paolo

Subjects
Re-treatment, IGRT-Clarity, Radiotherapy, Prostate Cancer, VMAT, Cyberknife System
Abstract

The management of prostate cancer recurrence following external beam radiotherapy is not defined yet. Stereotaxic body re-irradiation therapy, has shown encouraging results for local and biochemical control. From April 2017 to December 2020, 29 patients with prostate cancer recurrence were collected, joining the retrospective studies CyPro (prot. 46/19 OSS) and CLARO (Prot.19/20 OSS) trials. Patients were treated with Cyberknife (CK), or VMAT (Volumetric Modulated Arc Technique) system by IGRT (Image-Guided Radiation Therapy)/Clarity. By comparing the re-irradiation of two groups, we investigated urinary (GU), rectal (GI) toxicities and biochemical control. Furthermore, we dosimetrically compared the two techniques by rival plans. The VMAT-IGRT Clarity treatments were replanned with an optimized template developed for prostate VMAT-SBRT in FFF mode keeping the dose and fractionation scheduled for CK Group at 30 Gy in 5fx, prescribing at 80% isodose. 23% of patients experiencing grade 2 acute GU and 6% grade 2 acute GI in the CK group. 17% Acute GU toxicity was recorded in the VMAT-Clarity group. 8% grade 2 late toxicity was recorded in the VMAT-Clarity group. The dosimetric analysis shows that the VMAT-FFF will allow to deliver a dose biologically equivalent than with the CK, and reduce the toxicities that could arise.

Published
2022
Full Text
View/download PDF

33. Management of Metastatic Disease in Campania (MAMETIC): An Observational Multicenter Retrospective and Prospective Trial on Palliative Radiotherapy in an Italian Region. Study Protocol

Author

Di Franco,Rossella, Cascella,Marco, Fusco,Mario, Borzillo,Valentina, Scipilliti,Esmeralda, Ferraioli,Piera, Iannacone,Eva, De Palma,Giampaolo, Silvestro,Giustino, Gherardi,Federica, Buonopane,Sergio, Alberti,Domingo, Totaro,Giuseppe, Manzo,Roberto, Guida,Giovanna, Cuomo,Arturo, Pignata,Sandro, Di Napoli,Marilena, Rossetti,Sabrina, Celentano,Egidio, Crispo,Anna, Grimaldi,Maria, Ravo,Vincenzo, Muto,Paolo, Di Franco,Rossella, Cascella,Marco, Fusco,Mario, Borzillo,Valentina, Scipilliti,Esmeralda, Ferraioli,Piera, Iannacone,Eva, De Palma,Giampaolo, Silvestro,Giustino, Gherardi,Federica, Buonopane,Sergio, Alberti,Domingo, Totaro,Giuseppe, Manzo,Roberto, Guida,Giovanna, Cuomo,Arturo, Pignata,Sandro, Di Napoli,Marilena, Rossetti,Sabrina, Celentano,Egidio, Crispo,Anna, Grimaldi,Maria, Ravo,Vincenzo, and Muto,Paolo

Abstract

Rossella Di Franco,1 Marco Cascella,2 Mario Fusco,3 Valentina Borzillo,1 Esmeralda Scipilliti,1 Piera Ferraioli,1 Eva Iannacone,1 Giampaolo De Palma,1 Giustino Silvestro,1 Federica Gherardi,1 Sergio Buonopane,1 Domingo Alberti,1 Giuseppe Totaro,1 Roberto Manzo,1 Giovanna Guida,1 Arturo Cuomo,2 Sandro Pignata,4 Marilena Di Napoli,4 Sabrina Rossetti,4 Egidio Celentano,5 Anna Crispo,5 Maria Grimaldi,5 Vincenzo Ravo,1 Paolo Muto1 1Department of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italia; 2Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Napoli, Italia; 3Cancer Registry Unit, ASL Napoli 3 SUD, Napoli, Italia; 4Department of Uro-Gynecological, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italia; 5Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, ItaliaCorrespondence: Rossella Di Franco, Department of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italia, Email r.difranco@istitutotumori.na.itBackground: In the Italian Campania Region, 30.517 new cases of solid cancer have been diagnosed, in 2019. Of those, patients with metastatic disease are up to 20%. This class of patients is extremely diversified and copious, and the offer of radiotherapy may vary in different geographical areas within the same region. The aim of this observational multicenter retrospective and prospective trial is to evaluate the occurrence of metastatic metastatic cancer patients candidates for palliative radiotherapy in several areas of a great Italian region, the management of the disease through RT approaches, and its impact on cancer-related pain and overall HRQoL.Methods: This is a multicenter, retrospective and prospective observational investigation. The retrospective part of the study concerns all patients enrolled with a diagnosis of metastatic disease and treated in RT centers w

Published
2022

34. Reirradiation of Locally Recurrent Prostate Cancer with Cyberknife® System or Volumetric Modulated Arc Therapy (VMAT) and IGRT-Clarity®: Outcomes, Toxicities and Dosimetric Evaluation

Author

Di Franco, Rossella, primary, Borzillo, Valentina, additional, Scipilliti, Esmeralda, additional, Ametrano, Gianluca, additional, Serra, Marcello, additional, Arrichiello, Cecilia, additional, Savino, Federica, additional, De Martino, Fortuna, additional, D’Alesio, Valentina, additional, Cammarota, Fabrizio, additional, Crispo, Anna, additional, Pignata, Sandro, additional, Rossetti, Sabrina, additional, Quarto, Giuseppe, additional, and Muto, Paolo, additional

Published
2022
Full Text
View/download PDF

35. Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy

Author

Verzoni, Elena, primary, Pappagallo, Giovanni, additional, Alongi, Filippo, additional, Arcangeli, Stefano, additional, Francolini, Giulio, additional, Galanti, Daniele, additional, Galli, Luca, additional, Maruzzo, Marco, additional, Rossetti, Sabrina, additional, Siepe, Giambattista, additional, Triggiani, Luca, additional, Zucali, Paolo Andrea, additional, and D’Angelillo, Rolando Maria, additional

Published
2022
Full Text
View/download PDF

36. First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry

Author

Galli, Luca, primary, Chiuri, Vincenzo Emanuele, additional, Di Lorenzo, Giuseppe, additional, Pisconti, Salvatore, additional, Rossetti, Sabrina, additional, Sirotova, Zuzana, additional, Muto, Andrea, additional, Petrioli, Roberto, additional, De Tursi, Michele, additional, Sbrana, Andrea, additional, Francolini, Giulio, additional, Ardizzoia, Antonio, additional, Scavelli, Claudio, additional, Satta, Francesco, additional, Quadrini, Silvia, additional, Airoldi, Mario, additional, D’Aniello, Carmine, additional, Bonetti, Andrea, additional, Conforti, Serafino, additional, Aieta, Michele, additional, Beccaglia, Patrizia, additional, Maestri, Antonio, additional, and Fratino, Lucia, additional

Published
2022
Full Text
View/download PDF

37. Management of Metastatic Disease in Campania (MAMETIC): An Observational Multicenter Retrospective and Prospective Trial on Palliative Radiotherapy in an Italian Region. Study Protocol

Author

Di Franco, Rossella, primary, Cascella, Marco, additional, Fusco, Mario, additional, Borzillo, Valentina, additional, Scipilliti, Esmeralda, additional, Ferraioli, Piera, additional, Iannacone, Eva, additional, De Palma, Giampaolo, additional, Silvestro, Giustino, additional, Gherardi, Federica, additional, Buonopane, Sergio, additional, Alberti, Domingo, additional, Totaro, Giuseppe, additional, Manzo, Roberto, additional, Guida, Giovanna, additional, Cuomo, Arturo, additional, Pignata, Sandro, additional, Di Napoli, Marilena, additional, Rossetti, Sabrina, additional, Celentano, Egidio, additional, Crispo, Anna, additional, Grimaldi, Maria, additional, Ravo, Vincenzo, additional, and Muto, Paolo, additional

Published
2022
Full Text
View/download PDF

38. Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results

Author

Della Pepa, Chiara, Cavaliere, Carla, Rossetti, Sabrina, Di Napoli, Marilena, Cecere, Sabrina C., Crispo, Anna, De Sangro, Carlo, Rossi, Emanuela, Turitto, Dino, Germano, Domenico, Iovane, Gelsomina, Berretta, Massimiliano, D’Aniello, Carmine, Pisconti, Salvatore, Maiorino, Luigi, Daniele, Bruno, Gridelli, Cesare, Pignata, Sandro, and Facchini, Gaetano

Published
2017
Full Text
View/download PDF

39. First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry

Author

Galli, Luca, Chiuri, Vincenzo Emanuele, Di Lorenzo, Giuseppe, Pisconti, Salvatore, Rossetti, Sabrina, Sirotova, Zuzana, Muto, Andrea, Petrioli, Roberto, De Tursi, Michele, Sbrana, Andrea, Francolini, Giulio, Ardizzoia, Antonio, Scavelli, Claudio, Satta, Francesco, Quadrini, Silvia, Airoldi, Mario, D’Aniello, Carmine, Bonetti, Andrea, Conforti, Serafino, Aieta, Michele, Beccaglia, Patrizia, Maestri, Antonio, and Fratino, Lucia

Abstract

Background: With the availability of multiple treatment options for metastatic castration-resistant prostate cancer (mCRPC), new real-world data on disease management and drugs’ performance are needed.Methods: We described characteristics, management and clinical outcomes of patients receiving first-line mCRPC treatment within the Italian cohort of the real-world, prospective, international Prostate Cancer Registry. Patients were enrolled consecutively (2013-2016) in 32 Italian sites and followed for 3 years.Results: 238 patients were included: 157 received first-line abiraterone acetate plus prednisone (“abiraterone” thereafter) and 70 first-line docetaxel; 11 patients receiving other treatments were not considered. Compared with docetaxel-treated patients, those receiving abiraterone were significantly older (age ⩾75: 63.7% vs 38.6%), less frequently had a Gleason score >8 (48.2% vs 67.6%, p<0.005) at initial diagnosis, and more frequently an ECOG score ⩾1 (52.7% vs 36.2%, p<0.05) and comorbidities (76.4% vs 57.1%, p<0.05) at baseline; they reported a lower analgesic use (15.3% vs 30%, p<0.005). In the abiraterone group (median follow-up 22.1 months), median time to progression (TTP) and progression-free survival (PFS) were, respectively, 14.4 months (95% confidence interval, CI, 10.6-18.0) and 13.0 months (95% CI, 9.1-16.8); median overall survival (OS) was not reached, and 3-year OS was 59.1%. In the docetaxel treatment group (median follow-up 25.3 months), median TTP, PFS and OS were, respectively, 8.2 months (95% CI, 6.1-10.3), 8.2 months (95% CI, 5.8-10.3) and 33.2 months (95% CI, 19.2-not estimable).Conclusion: This investigation provided valuable information on the overall mCRPC treatment pattern and the effectiveness of first-line abiraterone and docetaxel in a population representative of everyday practice.

Published
2023
Full Text
View/download PDF

40. Oligometastatic prostate cancer treatment

Author

Rossetti, Sabrina, primary, Di Napoli, Marilena, additional, Pisano, Carmela, additional, C Cecere, Sabrina, additional, Tambaro, Rosa, additional, Ventriglia, Jole, additional, Passarelli, Anna, additional, Iovane, Gelsomina, additional, Feroce, Florinda, additional, Lastoria, Secondo, additional, Di Gennaro, Francesca, additional, Muto, Paolo, additional, Borzillo, Valentina, additional, Di Franco, Rossella, additional, Perdonà, Sisto, additional, Quarto, Giuseppe, additional, and Pignata, Sandro, additional

Published
2021
Full Text
View/download PDF

41. Reirradiation of Locally Recurrent Prostate Cancer with Cyberknife ® System or Volumetric Modulated Arc Therapy (VMAT) and IGRT-Clarity ® : Outcomes, Toxicities and Dosimetric Evaluation.

Author

Di Franco, Rossella, Borzillo, Valentina, Scipilliti, Esmeralda, Ametrano, Gianluca, Serra, Marcello, Arrichiello, Cecilia, Savino, Federica, De Martino, Fortuna, D'Alesio, Valentina, Cammarota, Fabrizio, Crispo, Anna, Pignata, Sandro, Rossetti, Sabrina, Quarto, Giuseppe, and Muto, Paolo

Subjects
INTERFERON gamma release tests, CANCER relapse, RETROSPECTIVE studies, TREATMENT effectiveness, COMPARATIVE studies, RADIOSURGERY, RADIOTHERAPY, PROSTATE tumors, RADIATION dosimetry, DRUG toxicity
Abstract

Simple Summary: From April 2017 to December 2020, 29 patients with prostate cancer recurrence were selected. They received Cyberknife® (CK) treatment (17 pts) or alternatively VMAT (Volumetric Modulated Arc Technique) therapy by IGRT (Image-Guided Radiation Therapy)/Clarity® (12 pts). Urinary (GU), rectal (GI) toxicities, and biochemical control were investigated. Further, the two techniques were dosimetrically compared by rival plans. The VMAT-IGRT Clarity® treatments were replanned applying a template developed for prostate VMAT-SBRT in FFF mode, keeping the same dose/fractionation scheduled for the CK Group (30 Gy in 5 fx at 80% isodose). In the CK group, 23% of patients experienced grade 2 acute GU, while 6% showed grade 2 acute GI. In the VMAT-Clarity® group, 17% of patients showed acute GU toxicity, while for 8% grade 2 late toxicity was recorded. The dosimetric analysis shows that VMAT-FFF allows to deliver a biological equivalent dose to CK, with the advantage of reducing the likelihood of toxicities arising. The management of prostate cancer recurrence following external beam radiotherapy is not defined yet. Stereotaxic body reirradiation therapy showed encouraging results for local and biochemical control. From April 2017 to December 2020, 29 patients with prostate cancer recurrence were collected, joining the retrospective studies CyPro (prot. 46/19 OSS) and CLARO (Prot. 19/20 OSS) trials. Patients received Cyberknife® treatment (17 pts) or alternatively VMAT (Volumetric Modulated Arc Technique) therapy by IGRT (Image-Guided Radiation Therapy)/Clarity® (12 pts). By comparing the reirradiation of two groups, urinary (GU), rectal (GI) toxicities, and biochemical control were investigated. Further, the two techniques were dosimetrically compared by rival plans. The VMAT-IGRT Clarity® treatments were replanned with an optimized template developed for prostate VMAT-SBRT in FFF mode keeping the same dose and fractionation scheduled for Cyberknife Group (30 Gy in 5 fx, at 80% isodose). In the CK group, 23% of patients experienced grade 2 acute GU, while 6% grade 2 acute GI. In the VMAT-Clarity® group, acute GU toxicity was recorded in 17%, while for 8% grade 2 late toxicity was recorded. The dosimetric analysis shows that the VMAT-FFF allows to deliver a biological equivalent dose to CK, with the advantage of reducing the likelihood of toxicities arising. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Management of Metastatic Disease in Campania (MAMETIC): Epidemiologic Data and Palliative Radiotherapy in an Italian Region. Study Protocol

Author

FRANCO, Rossella DI, primary, Cascella, Marco, additional, Fusco, Mario, additional, Borzillo, Valentina, additional, Ferraioli, Piera, additional, Scipilliti, Esmeralda, additional, D'Ippolito, Emma, additional, Petito, Angela, additional, Cuomo, Arturo, additional, Pignata, Sandro, additional, Napoli, Marilena Di, additional, Rossetti, Sabrina, additional, Celentano, Egidio, additional, Crispo, Anna, additional, Grimaldi, Maria, additional, and Muto, Paolo, additional

Published
2021
Full Text
View/download PDF

43. MA Nagement of METastatic Disease In Campania (MAMETIC): Epidemiologic Data and Palliative Radiotherapy in an Italian Region. Study Protocol

Author

Franco, Rossella Di, primary, Cascella, Marco, additional, Fusco, Mario, additional, Borzillo, Valentina, additional, Scipilliti, Esmeralda, additional, D'Ippolito, Emma, additional, Ferraioli, Piera, additional, Petito, Angela, additional, Cuomo, Arturo, additional, Pignata, Sandro, additional, Napoli, Marilena Di, additional, Rossetti, Sabrina, additional, Celentano, Egidio, additional, Crispo, Anna, additional, Grimaldi, Maria, additional, and Muto, Paolo, additional

Published
2021
Full Text
View/download PDF

44. From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer

Author

Tambaro, Rosa, primary, Napoli, Marilena Di, additional, Pisano, Carmela, additional, Cecere, Sabrina Chiara, additional, Attademo, Laura, additional, Rossetti, Sabrina, additional, Feroce, Florinda, additional, Setola, Sergio, additional, Califano, Daniela, additional, Russo, Daniela, additional, Spina, Anna, additional, Perdonà, Sisto, additional, Izzo, Alessandro, additional, and Pignata, Sandro, additional

Published
2021
Full Text
View/download PDF

45. Acute Toxicity in Hypofractionated/Stereotactic Prostate Radiotherapy of Elderly Patients: Use of the Image-guided Radio Therapy (IGRT) Clarity System

Author

DI FRANCO, ROSSELLA, primary, BORZILLO, VALENTINA, additional, ALBERTI, DOMINGO, additional, AMETRANO, GIANLUCA, additional, PETITO, ANGELA, additional, COPPOLARO, ANDREA, additional, TARANTINO, ILARIA, additional, ROSSETTI, SABRINA, additional, PIGNATA, SANDRO, additional, IOVANE, GELSOMINA, additional, PERDONÀ, SISTO, additional, QUARTO, GIUSEPPE, additional, GRIMALDI, GIOVANNI, additional, IZZO, ALESSANDRO, additional, CASTALDO, LUIGI, additional, MUSCARIELLO, RAFFAELE, additional, SERRA, MARCELLO, additional, FACCHINI, GAETANO, additional, and MUTO, PAOLO, additional

Published
2021
Full Text
View/download PDF

47. Abstract 6675: Basal NK activity and early Tregs inhibition predicts nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial

Author

Santagata, Sara, primary, Trotta, Anna Maria, additional, Rea, Giuseppina, additional, Napolitano, Maria, additional, Capiluongo, Anna, additional, D'Alterio, Crescenzo, additional, Napoli, Marilena Di, additional, Rossetti, Sabrina, additional, Pignata, Sandro, additional, and Scala, Stefania, additional

Published
2020
Full Text
View/download PDF

48. Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223).

Author

Caffo, Orazio, primary, Frantellizzi, Viviana, additional, Tucci, Marcello, additional, Galli, Luca, additional, Monari, Fabio, additional, Baldari, Sergio, additional, Masini, Cristina, additional, Bortolus, Roberto, additional, Facchini, Gaetano, additional, Alongi, Pierpaolo, additional, Zichi, Clizia, additional, Biasco, Elisa, additional, Fanti, Stefano, additional, Pignata, Salvatore, additional, Filice, Angelina, additional, Borsatti, Eugenio, additional, Rossetti, Sabrina, additional, Spada, Massimiliano, additional, Cortesi, Enrico, additional, and De Vincentis, Giuseppe, additional

Published
2020
Full Text
View/download PDF

49. Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study

Author

Berretta, Massimiliano, primary, Rinaldi, Luca, additional, Taibi, Rosaria, additional, Tralongo, Paolo, additional, Fulvi, Alberto, additional, Montesarchio, Vincenzo, additional, Madeddu, Giordano, additional, Magistri, Paolo, additional, Bimonte, Sabrina, additional, Trovò, Marco, additional, Gnagnarella, Patrizia, additional, Cuomo, Arturo, additional, Cascella, Marco, additional, Lleshi, Arben, additional, Nasti, Guglielmo, additional, Facchini, Sergio, additional, Fiorica, Francesco, additional, Di Francia, Raffaele, additional, Nunnari, Giuseppe, additional, Pellicanò, Giovanni Francesco, additional, Guglielmino, Aurelio, additional, Danova, Marco, additional, Rossetti, Sabrina, additional, Amore, Alfonso, additional, Crispo, Anna, additional, and Facchini, Gaetano, additional

Published
2020
Full Text
View/download PDF

50. Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223

Author

Caffo, Orazio, primary, Frantellizzi, Viviana, additional, Tucci, Marcello, additional, Galli, Luca, additional, Monari, Fabio, additional, Baldari, Sergio, additional, Masini, Cristina, additional, Bortolus, Roberto, additional, Facchini, Gaetano, additional, Alongi, Pierpaolo, additional, Agostini, Stefania, additional, Zichi, Clizia, additional, Biasco, Elisa, additional, Fanti, Stefano, additional, Pignata, Salvatore, additional, Filice, Angelina, additional, Borsatti, Eugenio, additional, Rossetti, Sabrina, additional, Spada, Massimiliano, additional, Cortesi, Enrico, additional, and De Vincentis, Giuseppe, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results